title: Hepatic non-Hodgkin lymphoma and hepatoblastoma complicating ataxia-telangiectasia.
abstract: Patients with ataxia-telangiectasia (A-T) have an increased risk of developing malignancies and are prone to severe early or late toxicity owing to chemotherapy. Leukemia and lymphoma account for about 85% of malignancies, but solid tumors have also been reported. We describe an unusual case of an 8-year-old child affected by A-T, who presented a primary hepatic B-cell non-Hodgkin lymphoma, treated with reduced doses of R-CHOP cycles plus rituximab. Three years later, the patient developed hepatoblastoma as a second malignancy. This case clearly emphasizes the need for intensive monitoring of A-T patients for early signs of malignancy and the opportunity to consider specific and modified regimens of chemotherapy.
authors: Dipartimento di Biomedicina dell' Età Evolutiva, University of Bari, Piazza Giulio Cesare, Bari, Italy. cecinativalerio@gmail.com
authors: Valerio
authors: V
authors: Cecinati
authors: Giampaolo
authors: G
authors: Arcamone
authors: Domenico De
authors: DD
authors: Mattia
authors: Nicola
authors: N
authors: Santoro
authors: Baldassarre
authors: B
authors: Martire
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001260:Ataxia Telangiectasia; D002648:Child; D002675:Child, Preschool; D018197:Hepatoblastoma / Q000628:therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D016609:Neoplasms, Second Primary / Q000628:therapy*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab